Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Dr Reddys Laboratories ADR repsg 1 Ord Shs RDY

Healthcare
Dr. Reddy’s Laboratories Limited is an India-based global pharmaceutical company. The Company offers a portfolio of products and services, including active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC). Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. The... see more

Recent & Breaking News (NYSE:RDY)

Dr. Reddy's Laboratories Announces the Launch of Sevelamer Carbonate for Oral Suspension in the U.S. Market

Business Wire December 27, 2018

Dr. Reddy's Laboratories Launches Aspirin and Extended-Release Dipyridamole Capsules in the U.S. Market

Business Wire December 24, 2018

Dr. Reddy’s announces the launch of over-the-counter store brand equivalent of Prilosec OTC® (Omeprazole Delayed-Release) Tablets, 20 mg in the U.S. Market

Business Wire December 11, 2018

Factors of Influence in 2018, Key Indicators and Opportunity within OSI, BorgWarner, Cubic, Dr. Reddy's Laboratories, Teck Resources, and Gardner Denver — New Research Emphasizes Economic Growth

GlobeNewswire December 10, 2018

Dr. Reddy's Laboratories Announces the Launch of Chlorthalidone Tablets, USP in the U.S. Market

Business Wire November 28, 2018

Dr. Reddy's Laboratories Announces Favorable Outcome in Buprenorphine and Naloxone Sublingual Film Patent Litigation

Business Wire November 20, 2018

Consolidated Research: 2018 Summary Expectations for Dr. Reddy's Laboratories, Union Pacific, Zimmer Biomet, Varian Medical, Sonic Automotive, and Axalta Coating — Fundamental Analysis, Key Performance Indications

GlobeNewswire November 1, 2018

Dr. Reddy's Laboratories Announces the Launch of Atomoxetine Capsules, USP in the U.S. Market

Business Wire October 31, 2018

Dr. Reddy’s Q2 & H1 FY19 Financial Results

Business Wire October 26, 2018

Dr. Reddy's Laboratories Receives Approval for Aspirin and Extended-Release Dipyridamole Capsules in the U.S. Market

Business Wire October 15, 2018

Dr. Reddy's Laboratories Announces the Sale of Its API Manufacturing Business Unit in Jeedimetla, Hyderabad

Business Wire October 15, 2018

Dr. Reddy's Laboratories announces the launch of Colesevelam Hydrochloride Tablets in the U.S. Market

Business Wire October 9, 2018

Dr. Reddy's to Release Q2 FY19 Results on October 26, 2018

Business Wire October 3, 2018

Dr. Reddy's Laboratories Announces the Sale of Cloderm® (clocortolone pivalate) Cream, 0.1% Franchise to EPI Health, LLC

Business Wire October 2, 2018

Dr. Reddy's Laboratories Announces the Launch of Imatinib Mesylate Tablets, USP in the U.S. Market

Business Wire October 1, 2018

Dr. Reddy’s Laboratories Announces That It Has Regained Worldwide Rights to DFA-02

Business Wire October 1, 2018

Dr. Reddy's Laboratories Announces the Sale of Its Antibiotic Manufacturing Site and Its Related Assets in Bristol, Tennessee

Business Wire October 1, 2018

Dr. Reddy's Laboratories Announces the Launch of Neostigmine Methylsulfate Injection, USP in the U.S. Market

Business Wire September 12, 2018

Dr. Reddy’s Q1 FY19 Financial Results

Business Wire July 26, 2018

Dr. Reddy's Laboratories Announces the Launch of Hervycta® (trastuzumab biosimilar) in India

Business Wire July 26, 2018